Evidence map›Paper›PMID 42486915›Full record

GuidelineBone marrow transplantation2026

Conditioning regimen for hematopoietic cell transplant in transfusion dependent thalassemia: Recommendations from the EBMT practice harmonisation and guidelines committee.

Mohammed Essa, Mattia Algeri, Mohsen Alzahrani, Francoise Bernaudin, Victoria Bordon, Sonali Choudhury, Josu de la Fuente, Fabio Giglio, Erfan Nur, Valeria Maria Pinto and 6 more

Abstract readPractice GuidelineReview
PubMed Publisher
In one paragraph

Guideline in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mohammed EssaKing Abdullah Specialist Children Hospital, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard, Riyadh, Saudi Arabia. essamo@mngha.med.sa.ORCID http://orcid.org/0000-0003-4860-0796
Mattia AlgeriDepartment of Pediatric Hematology-Oncology, Cell and Gene Therapy, IRCCS, Bambino Gesù Children's Hospital, Piazza Sant'Onofrio, 4 -, 00165, Rome, Italy.ORCID http://orcid.org/0000-0002-6673-2664
Mohsen AlzahraniKing Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard, Riyadh, Saudi Arabia.
Francoise BernaudinClinical Research Center, Referral Center for Sickle Cell disease, CHIC Hospital, Créteil SFGM-TC, Drepagreffe association, Créteil, France.
Victoria BordonPediatric Hematology &Oncology Department, Ghent University Hospital, Ghent, Belgium.ORCID http://orcid.org/0000-0001-8446-0220
Sonali ChoudhuryPediatric Hematology/Oncology Stem Cell transplant, Childrens Memorial Hospital, Chicago, IL, USA.
Josu de la FuenteDepartment of Pediatric and Haematology, Imperial College Healthcare NHS Trust, London, UK.ORCID http://orcid.org/0000-0002-0974-1249
Fabio GiglioUnit of Hematology and Bone Marrow Transplantation, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID http://orcid.org/0000-0003-4755-9533
Erfan NurDepartment of Clinical Hematology. Amsterdam UMC, Amsterdam, The Netherlands.
Valeria Maria PintoAOM-IRCCS Ospedale Policlinico San Martino. UO Ematologia e Terapie Cellulari, Genova, Italy.
Francesco OnidaHematology and BMT Centre, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.ORCID http://orcid.org/0000-0002-2991-3474
Annalisa RuggeriUnit of Hematology and Bone Marrow Transplantation, IRCCS Ospedale San Raffaele, Milan, Italy.ORCID http://orcid.org/0000-0002-7261-2765
Isabel Sánchez-OrtegaEBMT Chief Medical Officer, Executive Office, Barcelona, Spain.ORCID http://orcid.org/0009-0005-5519-9154
Akif YesilipekMedicalpark Antalya Hospital, Pediatric Hematology and Pediatric Stem Cell Transplantation Unit, Antalya, Turkey.ORCID http://orcid.org/0000-0002-4514-8637
Ibrahim Yakoub-AghaLille University Hospital, Lille University, INSERM U1286, Infinite, Lille, France.
Emanuele AngelucciAOM-IRCCS Ospedale Policlinico San Martino. UO Ematologia e Terapie Cellulari, Genova, Italy.ORCID http://orcid.org/0000-0002-6512-6080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) has represented a curative therapy for transfusion-dependent thalassemia (TDT) for over four decades. Despite major advances in conditioning regimens, graft-versus-host disease (GVHD) prophylaxis, and supportive care, substantial heterogeneity persists in patient preparation strategies and transplant protocols across centers. To address these practice variations and provide harmonized guidance, the European Society for Blood and Marrow Transplantation (EBMT) Practice Harmonization and Guidelines Committee convened an international expert workshop in Berlin (Germany) on September 29-30, 2025. A structured literature review was conducted in advance. Evidence was presented, critically appraised, and discussed in consensus-based sessions. Recommendations were formulated using the GRADE framework and approved by panel members and external reviewers. These guidelines summarize contemporary evidence regarding pre-transplant optimization, conditioning regimens according to age and donor type, management of iron overload and ineffective erythropoiesis, and approaches for alternative donor transplantation and gene therapy. The aim of this document is to provide practical, evidence-informed recommendations to standardize HCT practice and optimize outcomes for children and adults with TDT globally, including in resource-limited settings.

Indexed as

Blood TransfusionHematopoietic Stem Cell TransplantationThalassemiaTransplantation ConditioningHumans

Identifiers

PMID42486915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.